GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » EV-to-EBIT

4basebio (XTER:88Q) EV-to-EBIT : -26.18 (As of May. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is 4basebio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 4basebio's Enterprise Value is €208.95 Mil. 4basebio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-7.98 Mil. Therefore, 4basebio's EV-to-EBIT for today is -26.18.

The historical rank and industry rank for 4basebio's EV-to-EBIT or its related term are showing as below:

XTER:88Q' s EV-to-EBIT Range Over the Past 10 Years
Min: -129.14   Med: -16.99   Max: -10.37
Current: -26.1

During the past 4 years, the highest EV-to-EBIT of 4basebio was -10.37. The lowest was -129.14. And the median was -16.99.

XTER:88Q's EV-to-EBIT is ranked worse than
100% of 429 companies
in the Biotechnology industry
Industry Median: 9.84 vs XTER:88Q: -26.10

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. 4basebio's Enterprise Value for the quarter that ended in Jun. 2023 was €79.01 Mil. 4basebio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-7.98 Mil. 4basebio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -10.10%.


4basebio EV-to-EBIT Historical Data

The historical data trend for 4basebio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio EV-to-EBIT Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
- - -19.26 -14.80

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBIT Get a 7-Day Free Trial - -19.26 - -14.80 -

Competitive Comparison of 4basebio's EV-to-EBIT

For the Biotechnology subindustry, 4basebio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4basebio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4basebio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 4basebio's EV-to-EBIT falls into.



4basebio EV-to-EBIT Calculation

4basebio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=208.946/-7.981
=-26.18

4basebio's current Enterprise Value is €208.95 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4basebio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-7.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4basebio  (XTER:88Q) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

4basebio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-7.981/79.009625
=-10.10 %

4basebio's Enterprise Value for the quarter that ended in Jun. 2023 was €79.01 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4basebio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-7.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4basebio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of 4basebio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


4basebio (XTER:88Q) Business Description

Traded in Other Exchanges
Address
25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines